---
title: Follow-up of Persons With Multiple Sclerosis
nct_id: NCT03878836
overall_status: UNKNOWN
sponsor: Dokuz Eylul University
study_type: OBSERVATIONAL
primary_condition: Multiple Sclerosis
countries: Turkey (Türkiye)
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03878836.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03878836"
ct_last_update_post_date: 2019-03-18
last_seen_at: "2026-05-12T06:33:30.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Follow-up of Persons With Multiple Sclerosis

**Official Title:** Follow-up of Physical, Psychosocial and Cognitive Influences in Persons With Multiple Sclerosis: a Prospective Cohort Study

**NCT ID:** [NCT03878836](https://clinicaltrials.gov/study/NCT03878836)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 118
- **Lead Sponsor:** Dokuz Eylul University
- **Conditions:** Multiple Sclerosis
- **Start Date:** 2016-10-01
- **Completion Date:** 2021-08-01
- **CT.gov Last Update:** 2019-03-18

## Brief Summary

Multiple sclerosis (MS) is a chronic, progressive and demyelinating disease that affects more than 2.5 million people in the world and is frequently seen in young adults between 20 and 40 years of age, especially in women. Although the exact MS in Turkey is not known, it is estimated as 40/100,000. According to epidemiological studies in recent years, the prevalence and incidence of MS tend to increase. The most common clinical signs and symptoms include loss of sensation in the extremities, partial or total vision loss, acute or subacute motor dysfunction, cognitive impairment, double vision and gait dysfunction.

Currently, MS has no definitive cure. Progressive symptoms related to the disease need to be managed in order to increase and maintain the quality of life of individuals with MS. Pharmacological, physiotherapeutic and psychotherapeutic methods are the most effective effective methods in the management of symptoms. However, the efficacy of these methods has been demonstrated in clinical trials. The outcomes cannot be generalized to the entire MS population because of the inclusion and exclusion criteria that exist in clinical trials. In addition, clinical trials are conducted at a specified time interval (usually a short time interval is selected) and generally, short-term results are provided. In order to better understanding the course of MS, it is of utmost importance that long-term follow-up studies are carried out where as many patients are included and patients are followed from the date of initial diagnosis. The aim of this study is to investigate the change of physical, psychosocial and cognitive characteristics over time and the correlated variables.

The volunteers from MS patients who attend routine control of the MS outpatient clinic of Dokuz Eylül University Hospital will participate in the study. Physical and clinical assessments will be performed by physicians and physiotherapists, and cognitive evaluations will be performed by psychologists with 6-month intervals.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Diagnosis of multiple sclerosis
* Willingness to participate

Exclusion Criteria:

* Severe cognitive, physical, or psychiatric disability that prevent the assessments
```

## Interventions

- **Routine assessments** (OTHER) — Routine assessments, no specific intervention

## Primary Outcomes

- **Expanded Disability Status Scale** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_ — The Expanded Disability Status Scale is a method of quantifying disability in multiple sclerosis. The scale is based on a neurological examination by a clinician. It has steps from 0 to 10. The higher scores indicate higher neurological disability.

## Secondary Outcomes

- **Timed 25-Foot Walk** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Timed Up and Go test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Single Leg Stance Test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **6-Minute Walk Test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **12-Item Multiple sclerosis walking scale** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Modified Fatigue Impact Scale** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Epworth Sleepiness Scale** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Symbol Digit Modalities Test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **California Verbal Learning Test-II** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Revised Brief Visuospatial Memory Test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Godin Leisure Time Exercise Questionnaire** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Multiple Sclerosis International Quality of Life questionnaire** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Beck Depression Inventory** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Nine-Hole Peg Test** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **Nordic Musculoskeletal Questionnaire** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **painDETECT Questionnaire** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_
- **International Restless Legs Syndrome Study Group rating scale for restless legs syndrome** _(time frame: Change from Baseline at 6 Months, 18 Months, 30 Months, 42 Months, and 54 Months)_

## Locations (1)

- Dokuz Eylul University Hospital, MS Outpatient Clinic, Izmir, Turkey (Türkiye) — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.dokuz eylul university hospital, ms outpatient clinic|izmir||turkey (türkiye)` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03878836.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03878836*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*